SM
SMTI.US Sanara Medtech Inc
- Market cap
- USD 301M
- P/E
- -
- P/B
- 39.28x
- ROE
- -24.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SMTI.US undervalued?
Graham numberThe Graham number of Sanara Medtech Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sanara Medtech Inc fundamental analysis
No fundamental analysis for Sanara Medtech Inc yet.
Sanara Medtech Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sanara Medtech Inc
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial and full-thickness wounds, as well as first and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for …
Full company profileSanara Medtech Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sanara Medtech Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.51M | 6.30M | 5.84M | 11.8M | 15.6M | 24.1M | 45.8M | 65.0M | 86.7M | 103M | 112M |
| Gross Profit | 4.56M | 5.50M | 5.33M | 10.6M | 14.0M | 21.8M | 39.5M | 57.1M | 78.5M | 92.9M | 104M |
| Operating Income | -272K | 120K | -502K | -2.74M | -5.03M | -7.38M | -12.5M | -4.22M | -6.72M | 9.15M | 6.88M |
| EBITDA | -180K | 539K | -457K | -2.61M | -4.14M | -7.40M | -11.6M | -289K | -1.86M | 34.9M | 7.92M |
| Net Income | -416K | 331K | -601K | -2.81M | -4.36M | -7.92M | -7.94M | -4.30M | -9.66M | -37.6M | -1.87M |
| EPS | -0.38 | 0.16 | -0.28 | -1.32 | -0.76 | -1.08 | -1.00 | -0.52 | -1.14 | -4.36 | -0.21 |
| Balance Sheet | |||||||||||
| Total Assets | 2.17M | 2.22M | 3.04M | 11.1M | 9.83M | 36.4M | 61.0M | 73.9M | 88.1M | 72.9M | 72.2M |
| Total Liabilities | 2.59M | 2.12M | 1.93M | 4.72M | 3.99M | 6.24M | 19.3M | 29.3M | 49.2M | 67.0M | 64.6M |
| Shareholders' Equity | -423K | 103K | 1.11M | 6.61M | 6.15M | 30.6M | 41.8M | 44.8M | 39.4M | 5.93M | 7.67M |
| Cash & Short-term Investments | 833K | 463K | 732K | 6.61M | 455K | 18.7M | 8.96M | 5.15M | 15.9M | 16.6M | 16.8M |
| Total Debt | 1.62M | 1.20M | 1.50M | 2.10M | 481K | 425K | 819K | 11.8M | 32.3M | 48.2M | 48.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 409K | -140K | 277K | -2.17M | -4.03M | -4.81M | -5.55M | -3.25M | -23.8K | 6.79M | 4.64M |
| Capital Expenditure | 3.03K | 85.9K | 8.48K | 1.71M | 1.64M | 750K | 747K | 265K | 229K | 4.63M | 65.4K |
| Free Cash Flow | 406K | -226K | 269K | -3.87M | -5.68M | -5.56M | -6.30M | -3.51M | -253K | 2.16M | 4.57M |
| Ratios | |||||||||||
| ROE | - | 323.1% | -54.0% | -42.5% | -70.8% | -25.9% | -19.0% | -9.6% | -24.5% | -633.5% | -24.4% |
| ROA | -19.1% | 14.9% | -19.7% | -25.3% | -44.3% | -21.8% | -13.0% | -5.8% | -11.0% | -51.5% | -2.6% |
| Net Profit Margin | -7.5% | 5.3% | -10.3% | -23.9% | -27.9% | -32.8% | -17.3% | -6.6% | -11.2% | -36.4% | -1.7% |
| Debt to Equity | - | 11.70x | 1.35x | 0.32x | 0.08x | 0.01x | 0.02x | 0.26x | 0.82x | 8.13x | 6.35x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sanara Medtech Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 220K | 0.03 | - |
| 2021 | USD 443K | 0.06 | - |
| 2020 | USD 583K | 0.10 | - |
| 2019 | USD 10.00M | 4.69 | - |
| 2018 | USD 223K | 0.10 | - |
| 2017 | USD 32.5K | 0.02 | 9.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:100 on May 10, 2019.
Who owns Sanara Medtech Inc
- Insiders 49.50%
- Institutions 26.18%
- Public & others 24.32%
- Shares outstanding 9.18M
- Free float 3.76M
Top funds holding SMTI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 149K | 1.62% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 119K | 1.30% | 0.00% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 44.5K | 0.48% | -0.38% | Oct 2026 |
| Fidelity Small Cap Index | 36.4K | 0.40% | 0.00% | Aug 2026 |
| Vanguard Russell 2000 ETF | 28.2K | 0.31% | +44.53% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 26.7K | 0.29% | +0.26% | Oct 2026 |
| Fidelity Extended Market Index | 18.0K | 0.20% | -8.63% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 17.8K | 0.19% | +210.97% | Aug 2026 |
| iShares Micro-Cap ETF | 14.9K | 0.16% | 0.00% | Oct 2026 |
| AltShares Merger Arbitrage ETF | 14.6K | 0.16% | 0.00% | Aug 2026 |
| Schwab Small Cap Index | 11.8K | 0.13% | +41.56% | Sep 2026 |
| Russell Inv US Small Cap Equity Y | 11.0K | 0.12% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 9.61K | 0.10% | +186.32% | Jun 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 8.97K | 0.10% | +72.82% | Sep 2026 |
| BlackRock Advantage Small Cap Gr Instl | 8.50K | 0.09% | 0.00% | Sep 2026 |
| Avantis US Small Cap Equity ETF | 8.32K | 0.09% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 6.70K | 0.07% | -0.06% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 5.75K | 0.06% | -6.03% | Oct 2026 |
| Fidelity Series Total Market Index | 5.64K | 0.06% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 Growth ETF | 5.31K | 0.06% | +48.09% | Sep 2026 |
Top institutions holding SMTI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 249K | 2.71% | +8.77% | Jun 2026 |
| Vanguard Capital Management, LLC | 195K | 2.12% | +28.76% | Jun 2026 |
| Royal Bank of Canada | 131K | 1.43% | -0.30% | Jun 2026 |
| Stonebridge Wealth Management, LLC | 129K | 1.41% | -5.44% | Jun 2026 |
| Renaissance Technologies Corp | 114K | 1.24% | +69.29% | Sep 2026 |
| AQR Capital Management LLC | 112K | 1.22% | +180.95% | Jun 2026 |
| Geode Capital Management, LLC | 89.2K | 0.97% | +4.11% | Jun 2026 |
| The Goldman Sachs Group Inc | 74.2K | 0.81% | +243.75% | Jun 2026 |
| State Street Corp | 63.5K | 0.69% | +1.24% | Jun 2026 |
| Squarepoint Ops LLC | 53.8K | 0.59% | -26.89% | Jun 2026 |
| Jane Street Group LLC | 50.8K | 0.55% | +31.68% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 49.5K | 0.54% | -35.17% | Jun 2026 |
| Citadel Advisors Llc | 36.8K | 0.40% | +18.32% | Jun 2026 |
| Northern Trust Corp | 36.4K | 0.40% | +9.58% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 31.6K | 0.34% | 0.00% | Jun 2026 |
| Walleye Trading Advisors, LLC | 30.5K | 0.33% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 26.0K | 0.28% | +2.57% | Jun 2026 |
| Evernest Financial Advisors LLC | 25.7K | 0.28% | 0.00% | Jun 2026 |
| HILL ISLAND FINANCIAL LLC | 24.3K | 0.26% | 0.00% | Sep 2026 |
| Morgan Stanley - Brokerage Accounts | 23.6K | 0.26% | +20.31% | Jun 2026 |
Sanara Medtech Inc company profile
- Company name
- Sanara Medtech Inc
- Ticker
- SMTI.US
- Exchange
- USA Stocks
- Listed since
- Feb 22, 2011
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 108
- Fiscal year end
- December
- Address
- 1200 Summit Avenue, Fort Worth, TX, United States, 76102
- Phone
- 817 529 2300
- Website
- sanaramedtech.com
About Sanara Medtech Inc
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial and full-thickness wounds, as well as first and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Sanara Medtech Inc management
10- Mr. Ronald T. NixonExecutive Chairman · born 1956
- Mr. Seth D. YonPresident, CEO & Director · born 1975
- Ms. Elizabeth B. TaylorChief Financial Officer · born 1976
- Mr. Jacob A. WaldropChief Operating Officer · born 1982
- Ms. Ashley M. MackeyPrincipal Accounting Officer · born 1986
- Mr. Bill FitzgeraldChief Compliance Officer
- Mr. Nicholas Gachassin IIIGeneral Counsel · born 1967
- Ms. Tricia MattesonVice President of Marketing
- Mr. Tyler PalmerChief Corporate Development & Strategy Officer
- Ms. Nina BiondaChief R&D Officer